94590-46-2

Usage

Uses

Used in Pharmaceutical Industry:
3-aMino-2,3-dihydrobenzo[b][1,4]oxazepin-4(5H)-one is used as a tricyclic antidepressant for the treatment of mood disorders such as depression and anxiety. It is effective in managing symptoms like persistent sadness, loss of interest in activities, and feelings of hopelessness by modulating the levels of serotonin and norepinephrine in the brain.
Used in Mental Health Care:
Amoxapine serves as a therapeutic agent in mental health care, providing relief to patients suffering from depressive and anxiety disorders. Its mechanism of action involves the inhibition of neurotransmitter reuptake, leading to an increase in their levels in the brain and contributing to an improvement in mood and emotional well-being.

Upstream product

• 239097-68-8 (S)-3-(tert-butoxycarbonylamino)-2,3-dihydro-1,5(5H)-benzoxazepin-4-one 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 94590-41-7 3-[N-(1-carboethoxy-3-phenylpropyl)amino]-2,3-dihydro-1,5-benzoxazepin-4(5H)-one 

Relevant academic research and scientific papers

Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer''s disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer''s disease both prophylactically and therapeutically with such pharmaceutical compositions.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

BENZOTHIAZEPINE AND BENZOXAZEPINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS

The present invention relates to novel substituted benzothiazepines and benzoxazepines of the formula STR1 wherein R 1, R 2, R. sup. 7, R 8, R 9 and X are as defined below, and to novel intermediates used in the synthesis of such compounds. Such compounds are useful in the treatment and prevention of gastrointestinal disorders, pain and anxiety disorders.